



ASX ANNOUNCEMENT

25 May 2015

Long Serving Chairman Retires from TIS Board

Tissue Therapies announces that its long term Chairman, Roger Clarke, will resign from the Board on 31st May 2015. He became Chair at listing and has provided strong leadership throughout TIS' journey to date and in addition provided considerable support as an investor.

In its release of 13th April 2015, TIS stated that Roger Clarke had stepped down as Chair and that he would retire from the board in the short term by mutual agreement. Cherrell Hirst, the Interim Chair, praised his contribution saying "The Board expresses its sincere thanks to Roger for his very significant contribution over the many years since 2003. He has supported TIS through his leadership, his considerable experience and wisdom and his commitment of time and effort as well becoming a significant investor."

Cherrell Hirst
Interim Chairman

For more information

Dr Cherrell Hirst, Chairman Tissue Therapies Limited Cherrell@hirst.com Nigel Johnson, CEO Tissue Therapies Limited Tel: +61 7 3334 3900 Email: n.johnson@tissuetherapies.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au
--	--

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.

Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company also has a licence for commercialisation of various patent families related to wound healing and other therapeutic uses. Tissue Therapies Limited's shares are traded on the Australia, Berlin and Frankfurt stock exchanges.

For more information, please visit www.tissuetherapies.com.